Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyrtec-D OTC switch gets FDA approval

Executive Summary

Johnson & Johnson's McNeil Consumer Healthcare subsidiary could launch Zyrtec-D behind the counter before the end of the year. FDA approved the antihistamine and nasal decongestant for nonprescription use in adults and children 12 years and older Nov. 9. Zyrtec-D (cetirizine HCl 5 mg and pseudoephedrine HCl 120 mg) has been available as a prescription drug since 2001. Under the Combat Meth Act, Zyrtec-D is required to be sold behind the counter because it contains pseudoephedrine, according to McNeil. J&J acquired OTC licensing rights for Zyrtec when it purchased Pfizer Consumer Healthcare in 2006...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS049010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel